Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer

Open access

Published version of a preprint

Abstract

Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate cancer. The efficacy of ADT has not been rigorously evaluated by demonstrating suppression of prostatic androgen activity at the target tissue and molecular level. We determined the efficacy and consistency of medical castration in suppressing prostatic androgen levels and androgen-regulated gene expression. Androgen levels and androgen-regulated gene expression (by microarray profiling, quantitative reverse transcription-PCR, and immunohistochemistry) were measured in prostate samples from a clinical trial of short-term castration (1 month) using the gonadotropin-releasing hormone antagonist, Acyline, versus placebo in healthy men. To assess the effects of long-term ADT, gene expression measurements were evaluated at baseline and after 3, 6, and 9 months of neoadjuvant ADT in prostatectomy samples from men with localized prostate cancer. Medical castration reduced tissue androgens by 75% and reduced the expression of several androgen-regulated genes (NDRG1, FKBP5, and TMPRSS2). However, many androgen-responsive genes, including the androgen receptor (AR) and prostate-specific antigen (PSA), were not suppressed after short-term castration or after 9 months of neoadjuvant ADT. Significant heterogeneity in PSA and AR protein expression was observed in prostate cancer samples at each time point of ADT. Medical castration based on serum testosterone levels cannot be equated with androgen ablation in the prostate microenvironment. Standard androgen deprivation does not consistently suppress androgen-dependent gene expression. Suboptimal suppression of tumoral androgen activity may lead to adaptive cellular changes allowing prostate cancer cell survival in a low androgen environment. Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment. [Cancer Res 2007;67(10):5033–41]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-3332

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 533

Metadata

Authors
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., Bremner, W. J., Gleave, M. E., & Nelson, P. S.
Affiliations
  • Fred Hutch Cancer Center (US)
  • VA Puget Sound Health Care System (US)
  • Vancouver General Hospital (CA)
  • University of Washington (US)
  • Oregon National Primate Research Center (US)
  • 2Medicine,
Venue
Cancer Research
Published
2007-05-15
Volume
67
Issue
10
Pages
5033-5041
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2137996608
Cited by
529
References
50
Citations by year
2026: 6 · 2025: 4 · 2024: 9 · 2023: 19 · 2022: 10 · 2021: 16 · 2020: 21 · 2019: 18 · 2018: 24 · 2017: 22 · 2016: 28 · 2015: 42 · 2014: 43 · 2013: 50 · 2012: 40
FWCI
35.56
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Prostate Cancer Foundation
  • Michael Smith Health Research BC
  • National Institutes of Health (RR 00163)
  • Oregon National Primate Research Center (RR00163)
  • National Institute on Aging (K23AG027238)
  • National Cancer Institute (P50-CA97186, T32 CA09515-21, K23CA122820, T32CA009515, P50CA097186)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065204, DK65204, DK 65083, K23DK065083)
  • National Institute of Child Health and Human Development (U54 HD42454, RR00163)
  • National Center for Research Resources (RR-0163)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD042454, U54HD42454)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
castration-resistant prostate cancer, androgen deprivation therapy, androgen-regulated gene expression, medical castration, GnRH antagonist, acyline, neoadjuvant androgen deprivation, prostate-specific antigen, androgen receptor, TMPRSS2, NDRG1, FKBP5, localized prostate cancer
MeSH terms
Adult, Androgens, Humans, Gonadotropin-Releasing Hormone, Male, Middle Aged, Oligopeptides, Orchiectomy, Prostatic Neoplasms, Testosterone, Gene Expression Regulation, Neoplastic, Prostate-Specific Antigen, Reverse Transcriptase Polymerase Chain Reaction, Neoadjuvant Therapy, Oligonucleotide Array Sequence Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-3332
The paper
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., Bremner, W. J., Gleave, M. E., & Nelson, P. S. (2007). Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-3332

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.